- Home
- GLPG vs LTC Comparison
GLPG vs LTC Comparison
Compare GLPG & LTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | LTC |
|---|---|---|
| Founded | 1999 | 1992 |
| Country | Belgium | United States |
| Employees | 704 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | GLPG | LTC |
|---|---|---|
| Price | $32.47 | $38.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | $36.50 | ★ $39.00 |
| AVG Volume (30 Days) | 90.9K | ★ 362.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.87% |
| EPS Growth | N/A | ★ 23.53 |
| EPS | N/A | ★ 2.52 |
| Revenue | N/A | ★ $262,854,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.24 |
| P/E Ratio | ★ N/A | $15.40 |
| Revenue Growth | N/A | ★ 25.26 |
| 52 Week Low | $22.59 | $31.70 |
| 52 Week High | $37.78 | $40.80 |
Technical Indicators
Market Signals| Indicator | GLPG | LTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 53.23 |
| Support Level | $32.07 | $38.48 |
| Resistance Level | $33.56 | $40.43 |
| Average True Range (ATR) | 0.79 | 0.81 |
| MACD | -0.15 | -0.20 |
| Stochastic Oscillator | 1.66 | 35.90 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.